Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Obinutuzumab or Ibrutinib in Japanese CLL/SLL
NCT05105841Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by AbbVie Inc.. Started Nov 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05105841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105841.